⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727484 | 1.00 | — | — | |
| SCHEMBL2985550 | 1.00 | — | — | |
| SCHEMBL17162480 | 1.00 | — | — | |
| SCHEMBL2909263 | 1.00 | — | — | |
| SCHEMBL2911929 | 1.00 | — | — | |
| SCHEMBL17162469 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2918760 | 0.99 | — | — | |
| SCHEMBL3043623 | 0.90 | — | — | |
| SCHEMBL3792793 | 0.90 | — | — | |
| SCHEMBL3038336 | 0.87 | PER2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | claimed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | claimed |
| EP-1735304-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-01-07 | — | — | EP | claimed |
| US-7419989-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | claimed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | claimed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | claimed |
| US-9873692-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9630960-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9353106-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150291580-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | ALFASIGMA S.P.A. (IT) | 2008-07-24 | — | — | US | disclosed |
| US-20080132491-A1 | Indazole-carboxamide compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-05 | — | — | US | disclosed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | ALFASIGMA S.P.A. (IT) | 2007-12-06 | — | — | US | disclosed |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | ALFASIGMA S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | disclosed |